AAAAAA
Results: 26-41/41
Authors:
Hanauer, SB
Greenberger, NJ
Citation: Sb. Hanauer et Nj. Greenberger, Updating the approach to Crohn's disease, HOSP PRACT, 34(8), 1999, pp. 77
Authors:
Sandborn, WJ
Hanauer, SB
Citation: Wj. Sandborn et Sb. Hanauer, Antitumor necrosis factor therapy for inflammatory bowel disease: A reviewof agents, pharmacology, clinical results, and safety, INFLAMM B D, 5(2), 1999, pp. 119-133
Authors:
Cohen, RD
Brodsky, AL
Hanauer, SB
Citation: Rd. Cohen et al., A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin, INFLAMM B D, 5(1), 1999, pp. 1-10
Authors:
Stein, RB
Hanauer, SB
Citation: Rb. Stein et Sb. Hanauer, Medical therapy for inflammatory bowel disease, GASTRO CLIN, 28(2), 1999, pp. 297
Authors:
Hanauer, SB
Citation: Sb. Hanauer, Review article: safety of infliximab in clinical trials, ALIM PHARM, 13, 1999, pp. 16-22
Authors:
Hanauer, SB
Citation: Sb. Hanauer, Medical therapy for Crohn's disease, CURR OPIN G, 15(4), 1999, pp. 308-314
Authors:
Present, DH
Rutgeerts, P
Targan, S
Hanauer, SB
Mayer, L
van Hogezand, RA
Podolsky, DK
Sands, BE
Braakman, T
DeWoody, KL
Schaible, TF
van Deventer, SJH
Citation: Dh. Present et al., Infliximab for the treatment of fistulas in patients with Crohn's disease, N ENG J MED, 340(18), 1999, pp. 1398-1405
Authors:
Hanauer, SB
Citation: Sb. Hanauer, Crossing borders in IBD - Clinical symposium - Barcelona, October 2, 1998 - Introduction, DRUGS TODAY, 35, 1999, pp. 3-3
Authors:
Pena, AS
Meuwissen, SGM
Falke, TJM
Cuesta, MA
Hanauer, SB
Rutgeerts, P
Tremaine, BW
Gassull, MA
Cortot, A
Cohen, Z
Citation: As. Pena et al., Inflammatory bowel disease. A case presentation from Amsterdam with a panel discussion in Barcelona, DRUGS TODAY, 35, 1999, pp. 149-159
Authors:
Hanauer, SB
Citation: Sb. Hanauer, Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis - Commentary, GUT, 44(4), 1999, pp. 455-455
Authors:
Ehrenpreis, ED
Kane, SV
Cohen, LB
Cohen, RD
Hanauer, SB
Citation: Ed. Ehrenpreis et al., Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial, GASTROENTY, 117(6), 1999, pp. 1271-1277
Authors:
Rutgeerts, P
D'Haens, G
Targan, S
Vasiliauskas, E
Hanauer, SB
Present, DH
Mayer, L
Van Hogezand, RA
Braakman, T
DeWoody, KL
Schaible, TF
Van Deventer, SJH
Citation: P. Rutgeerts et al., Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, GASTROENTY, 117(4), 1999, pp. 761-769
Authors:
Sandborn, WJ
Tremaine, WJ
Wolf, DC
Targan, SR
Sninsky, CA
Sutherland, LR
Hanauer, SB
McDonald, JWD
Feagan, BG
Fedorak, RN
Isaacs, KL
Pike, MG
Mays, DC
Lipsky, JJ
Gordon, S
Kleoudis, CS
Murdock, RH
Citation: Wj. Sandborn et al., Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease, GASTROENTY, 117(3), 1999, pp. 527-535
Authors:
Sands, BE
Bank, S
Sninsky, CA
Robinson, M
Katz, S
Singleton, JW
Miner, PB
Safdi, MA
Galandiuk, S
Hanauer, SB
Varilek, GW
Buchman, AL
Rodgers, VD
Salzberg, B
Cai, B
Loewy, J
DeBruin, MF
Rogge, H
Shapiro, M
Schwertschlag, US
Citation: Be. Sands et al., Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease, GASTROENTY, 117(1), 1999, pp. 58-64
Authors:
Cohen, RD
Stein, R
Hanauer, SB
Citation: Rd. Cohen et al., Intravenous cyclosporin in ulcerative colitis: A five-year experience, AM J GASTRO, 94(6), 1999, pp. 1587-1592
Authors:
Hanauer, SB
Stein, RB
Citation: Sb. Hanauer et Rb. Stein, Medical therapy, OPERATIVE STRATEGIES IN INFLAMMATORY BOWEL DISEASE, 1999, pp. 138-149